Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New MRI technique aims to spot hidden heart problems

NCT ID NCT06854458

Diagnosis Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 2 times

Summary

This study will enroll 1,000 adults aged 35-85 with chest pain or shortness of breath to see if a new, detailed MRI blood flow measurement can more accurately diagnose heart disease than standard MRI. Participants will receive a contrast agent called Gadavist during stress and rest imaging. The goal is to improve diagnosis and reduce unnecessary invasive procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Gadavist (gadobutrol contrast agent)
What this could lead to
If successful, this could make heart disease diagnosis more accurate and help doctors better understand its severity without invasive procedures.
What could go wrong
This is an observational study, not a treatment trial. The new MRI method may not prove more useful than standard imaging, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. male or female at age 35-85 years, 2. presence of either of the following sign/symptom that led to a referral to stress cardiac magnetic resonance imaging: 1. chest pain or anginal equivalent, or 2. abnormal electrocardiogram with a suspicion of coronary artery disease 3. Intermediate or high risk of significant coronary disease based on at least 1 of the following conditions: a) patient age \> 45 for male, 50 for female b) Diabetes, hypertension, or hypercholesterolemia: by either history or medical treatment c) family history of premature coronary disease: first degree relative at age \<= 55 male and \<=65 female d) history of smoking of \> 10 packed-years e) post-menopausal state \>5 years f) any chronic inflammatory conditions d) Body mass index \> 30 e) Any medical documentation of coronary or peripheral artery disease Exclusion Criteria: 1. Acute myocardial infarction within the past 30 days prior to cardiac magnetic resonance imaging 2. Confirmed diagnosis of any significant non-coronary cardiac conditions below: 1. any severe-grade valvular heart disease, 2. left ventricular ejection fraction \<40% from any known non-coronary causes, 3. infiltrative cardiomyopathy, 4. hypertrophic cardiomyopathy, 5. pericardial disease with significant constriction, or 3. active pregnancy, 4. any competing conditions leading to an expected survival of \< 2 years 5. contraindication to vasodilator (regadenoson or adenosine) 6. metallic device or object that poses an magnetic resonance imaging safety hazard 7. metallic device with a high likelihood of non-diagnostic cardiac magnetic resonance images

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac magnetic resonance imaging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac magnetic resonance imaging Ischemic heart disease (IHD) Myocardial blood flow

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    13 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Atrium Health - Sanger Heart & Vascular Institute

    RECRUITING

    Charlotte, North Carolina, 28204, United States

  • Beth Israel Deaconess Medical Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

  • Cleveland Clinic

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Houston Methodist Hospital

    RECRUITING

    Houston, Texas, 77030, United States

  • St. Francis Hospital and Heart Center

    RECRUITING

    Roslyn, New York, 11576, United States

  • The Ohio State University

    RECRUITING

    Columbus, Ohio, 43210, United States

  • University of California San Francisco

    RECRUITING

    San Francisco, California, 94107, United States

  • University of Utah

    RECRUITING

    Salt Lake City, Utah, 84108, United States

  • University of Virginia

    RECRUITING

    Charlottesville, Virginia, 22908, United States

  • UofL Health - Heart Hospital

    RECRUITING

    Louisville, Kentucky, 40202, United States

  • Vanderbilt University Medical Center

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Virginia Commonwealth University

    RECRUITING

    Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.